Physician Wealth Advisors Inc. Takes Position in Zoetis Inc. (NYSE:ZTS)

Physician Wealth Advisors Inc. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 598 shares of the company’s stock, valued at approximately $97,000.

A number of other large investors have also recently added to or reduced their stakes in ZTS. Mission Wealth Management LP raised its position in Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its holdings in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC lifted its position in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after buying an additional 62 shares during the last quarter. Procyon Advisors LLC boosted its stake in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after acquiring an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last quarter. 0.16% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of ZTS opened at $163.03 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The stock has a market capitalization of $73.00 billion, a PE ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a 50-day simple moving average of $166.40 and a 200-day simple moving average of $174.44.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis’s payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZTS. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.